# Raynar Flagship Factsheet August 2020 Sub Fund of . EFG Silverstone SICAV-RAIF

#### Fund Manager:



Portfolio Manager: Philip Rodrigs

First Day of Trading: 1 June 2020

Fund Assets Under Management: £20.4m

Firm Assets Under Management £56.5m

**Custodian:** EFG Bank (Luxembourg) S.A.

AIFM EFG Fund Management S.A.

> Administrator: HSBC France, Luxembourg Branch

Auditor: BDO Audit S.A. Luxembourg

Feb

-9.22%

-4.11%

23.88%

Jan

1.78%


2019

2020

### Fund Objective:

To achieve capital growth over the medium term with an absolute focus on stock selection, unconstrained in its approach to building a high conviction portfolio of attractive risk vs return high conviction investments from across the UK equity market, with a likely predominance of small and micro sized companies. During periods with insufficient opportunities, unallocated capital will be preserved utilising the flexibility to invest in cash, beta hedging instruments and other asset classes.

## FOR PROFESSIONAL INVESTORS ONLY



#### Past performance is not a reliable indicator of future performance.

6.50%

7.80%

43.25%

3.57%

9.77%

\*Raynar Flagship performance in dark blue shows the net asset values of Class A Distribution shares in GBP from launch sourced from Bloomberg net of all fees and costs. Past performance from 1<sup>st</sup> August 2019 to 29<sup>th</sup> May 2020 shown in light blue is an illustrative scenario. Using Bloomberg, actual weights of holdings and cash held by Raynar Flagship as at end of June 2020 have been applied to the start date of 1<sup>st</sup> July 2019 and a performance simulation of that portfolio generated, with the same fee and cost structure applied, rebased to 100 as of 29<sup>th</sup> May 2020.

## Raynar Flagship Factshee August 2020 Sub Fund of: EFG Silverstone SICAV-RAIF

Top Ten Equities	Holding	Top Ten Investment Themes	Allocation
MaxCyte	7.2%	Internet Enabled Retail/Services	20.2%
LoopUp	7.0%	Capital Preservation	14.8%
Gear4Music	5.5%	Medical Technology	14.7%
CentralNic	4.8%	Home Working Connectivity	14.0%
Gamesys	4.6%	Internet Utilities	8.2%
Purplebricks	4.3%	Recession Beneficiaries	7.7%
Avacta	4.3%	Gold and Gold Miners	7.6%
BigBlu Broadband	4.2%	Market Volatility Beneficiaries	3.9%
Kape Technologies	3.3%	Government Stimulus Beneficiaries	3.5%
FRP Advisory	3.1%	Eating In Beneficiaries	2.8%

#### MaxCyte

A valuable investment maxim is to avoid investment propositions that 'sound too good to be true'. But sometimes there are exceptions that prove that rule, and **MaxCyte** is a top holding on that premise.

In recent decades there have been waves of innovation as fundamental new discoveries lead to major new classes of treatments. At the cutting edge is a new method which uses a patient's own blood cells to fight disease. By taking a patient's own blood, inserting a drug or a DNA instruction into tens of millions of those blood cells and returning them to the patient (with much reduced rejection risk), the patient's own cells can fight disease. Despite sounding like science fiction, early examples of this new class of therapy are producing very significant results.

So how do you inject DNA instructions into millions of cells? Some use a modified virus, which takes many days. **MaxCyte's** unique and strongly patented Flow Electroporation technology can use electrical pulses to deliver the payload within a day – a game-changer that has seen **MaxCyte** sign up a succession of industry leaders to their roster. Can **MaxCyte** really have a globally significant medical technology platform that could enable countless therapies and cures? At £275m valuation (up over 100% since initial purchase) it may seem like this minnow could be too good to be true: however **MaxCyte** is held with the same degree of conviction as that demonstrated by the firm's customers.

Contact Details	Raynar Flagship Share Classes	A Class	B Class
	Inception Date	29 <sup>th</sup> May 2020	24 <sup>th</sup> August 2020
Head of Client Relations: Jon Garland j <u>on@raynarpm.com</u> T: 0207 1234 606 M: 0745 809 2791	Status	Open	Open
	Minimum Initial Investment	£200,000	£5,000,000
	Subscription	Daily, zero fee	Daily, zero fee
	Redemption	Monthly, zero fee	Monthly, zero fee
	Redemption Notice	20 Business Days	20 Business Days
	Annual Management Charge	1.00%	0.75%
Websites:	Performance Fee	20%	20%
<u>www.raynarpm.com</u> www.efg-fundmanagement.com	Hurdle Rate	5% per annum	10% per annum
	High Water Mark	Yes – Lifetime	Yes – Lifetime
Enquiries Form: www.raynarpm.com/investor-enquiries/	Distribution/Accumulation	Distribution	Distribution
	ISIN	LU2076760391	LU2203806885
	Bloomberg Ticker	EFSRFGI LX	EFSRFBG LX

All data correct as of the end of August 2020. Investment Themes are categorisations chosen by the portfolio manager which, in their opinion, best describes the predominant driver of the underlying investments in each category.

The investment strategies employed by Raynar Portfolio Management are intended only for those persons who may be categorised as professional clients. Raynar Portfolio Management is a trading name of Met Facilities LLP which is authorised and regulated by the Financial Conduct Authority (FRN: 587084). Met Facilities LLP is the investment manager of the Fund. EFG Fund Management SA is the Alternative Investment Fund Manager (AIFM).